Back to top
more

Cempra, Inc. (CEMP)

(Delayed Data from NSDQ)

$2.33 USD

2.33
511,620

+0.03 (1.09%)

Updated Nov 3, 2017 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

Melinta Therapeutics, Inc. [CEMP]

Reports for Purchase

Showing records 1 - 20 ( 89 total )

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 1

10/31/2017

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CEMP

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 2

10/02/2017

Industry Report

Pages: 19

Healthcare: Fourth Quarter 2017 Preview Note

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 50.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 3

08/10/2017

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 4

08/10/2017

Company Report

Pages: 2

Melinta Merger - Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 5

08/09/2017

Company Report

Pages: 8

To Merge With Melinta, Creating Antibiotic-Focused Biopharma Firm

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 6

05/02/2017

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 7

05/01/2017

Company Report

Pages: 7

Taksta?s Phase 2/3 Fully Enrolled; Data in 30 rBJI Patients in 2H''17

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 8

05/01/2017

Company Report

Pages: 2

Strategic Review Underway - Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 9

03/29/2017

Company Report

Pages: 2

Final Nail in the Soli Coffin? - Changing to a Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 10

03/01/2017

Company Report

Pages: 8

Soli''s Effectively Dq?d; Taksta?s Bone Inf Ph2/3 Almost Fully Enrolled

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 11

03/01/2017

Company Report

Pages: 2

Reassessing Valuation - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 12

03/01/2017

Company Report

Pages: 2

Gonorrhea Setback Leaves Cash Burning Sensation - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 13

03/01/2017

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 14

02/27/2017

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 15

02/27/2017

Company Report

Pages: 13

Taksta Hits on First ABSSSI Ph3; Bone Inf Data Ahead; Upgrade to Buy, $8 PT

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 50.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 16

02/27/2017

Company Report

Pages: 2

Skin in the Game - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 17

01/03/2017

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 18

12/30/2016

Company Report

Pages: 2

FDA Busts a CAP - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 19

12/30/2016

Company Report

Pages: 8

FDA Issues CRL, Requires Large Safety Study For Solithromycin?s Approval

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Melinta Therapeutics, Inc.

Industry: Medical - Drugs

Record: 20

12/15/2016

Daily Note

Pages: 15

Antibiotics Update - Upcoming Events and Catalysts

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 50.00

Research Provided by a Third Party